Advanced Cell enrolls first patients in 2 clinical trials for eye disease stem cell treatments Print E-mail
By Olivia D'Orazio - Proactiveinvestors.com   
Thursday, 16 June 2011 16:45
Advanced Cell Technology (OTCBB:ACTC) announced Thursday the enrollment of the first patients in its two Phase 1/2 clinical trials for the treatment of Stargardt's Macular Dystrophy (SMD) and Dry Age-Related Macular Dystrophy (Dry AMD), both degenerative eye diseases. The regenerative medicine-focused biotech company will use retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs) to treat SMD and Dry AMD, which are degenerative diseases that cause the loss of photoreceptors in the retina of the eye, eventually resulting in blindness.

The treatment works by implanting hESCs in the patients' eyes, to replace degenerative RPE cells in the eye before all vision function is lost. The hESCs have the ability to differentiate into any cell type and can demonstrate the full transition in state from hESC to RPE cell.

Advanced Cell said the study is intended to determine the safety and tolerability of the RPE cells one year after transplantation. The patients were enrolled at the Jules Stein Eye Institute at the University of California, Los Angeles (UCLA).

"The enrollment of the first patients in our two clinical trials marks an important step forward for the field of regenerative medicine," said CEO Gary Rabin.

"If these therapies work as we hope they will, particularly with small volumes of cells, then we should be in an excellent position to take advantage of our patented techniques for manufacturing large numbers of doses of RPE cells that can be conveniently stored and shipped to clinicians, following the basic manufacturing and distribution systems already familiar to pharmaceutical and biotech companies."

Stargardt's is one of the most common forms of macular degeneration in the world, usually starting in children between 10 to 20 years of age.

Dry AMD, meanwhile, is seen in older people, typically starting between the ages of 66 to 74, with prevelance increasing with age.


Proactiveinvestors is a leading news organisation and event business with offices in New York, Sydney, Toronto and London. The Company is a publisher and is not registered with the US Securities Exchange Commission or Ontario Securities Commission. Please read our full terms and conditions here http://www.proactiveinvestors.com/pages/terms




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter